Selection and identification of a specific peptide binding to ovarian cancer cells from a phage-displayed peptide library

Objectives Ovarian cancer is one of the most fatal gynecological malignancies. It is emergently needed to select a novel molecular fragment as a targeting element for the future development of molecular imaging diagnosis and targeting chemotherapy to ovarian cancer. Results After five rounds of biop...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biotechnology letters 2022-08, Vol.44 (8), p.951-960
Hauptverfasser: Gao, Qian, Chen, Lirong, Jia, Chenshuang, Yuan, Yue, Li, Xinyao, Lu, Zheng, Feng, Yang, Zhao, Ruixia, Zhao, Xuewei, Wang, Yiwen, Cheng, Sinan, Zhang, Caixia, Xu, Jie, Shu, Zhan, Duan, Wei, Nie, Guochao, Xiao, Li, Hou, Yingchun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives Ovarian cancer is one of the most fatal gynecological malignancies. It is emergently needed to select a novel molecular fragment as a targeting element for the future development of molecular imaging diagnosis and targeting chemotherapy to ovarian cancer. Results After five rounds of biopanning, a total of 44 positive phage clones were selected from final phage displayed peptide library. Nine consensus sequences were found based on the assay of sequencing results, then one clone of each consensus group was characterized and identified further by immunofluorescence assay. The result showed the phage clone R20 presents best targeting capacity. Then we synthesized peptide (OSP2) clone R20 displayed, it was characterized with high specificity and sensitivity binding to human ovarian cancer by a tissue chip assay. The target of OSP2 was predicted and docked as human carbonic anhydrase XII (CA12), an important protein usually deregulated in cancer. Conclusions Taken together, OSP2 and its target indicate a novel investigation way in future to develop novel agent or drug delivery formulation for molecular imaging diagnosis and targeting chemotherapy of ovarian cancer.
ISSN:0141-5492
1573-6776
DOI:10.1007/s10529-022-03263-w